The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Safety and Immunogenicity Trial in Adult Volunteers of a Human Papillomavirus 16 L1 Virus-Like Particle Vaccine
Abstract
BACKGROUND: Studies in animal models have shown that systemic immunization with a papillomavirus virus-like particle (VLP) vaccine composed of L1, a major structural viral protein, can confer protection against subsequent experimental challenge with the homologous virus. Here we report results of a double-blind, placebo-controlled, dose-escalation trial to evaluate the safety and immunogenicity of a human papillomavirus (HPV) type 16 (HPV16) L1 VLP vaccine in healthy adults. METHODS: Volunteers were given intramuscular injections with placebo or with 10- or 50-microg doses of HPV16 L1 VLP vaccine given without adjuvant or with alum or MF59 as adjuvants at 0, 1, and 4 months. All vaccine recipients were monitored for clinical signs and symptoms for 7 days after each inoculation. Immune responses were measured by an HPV16 L1 VLP-based enzyme-linked immunosorbent assay (ELISA) and by an HPV16 pseudovirion neutralization assay. The antibody titers were given as the reciprocals of the highest dilution showing positive reactivity in each assay. All statistical tests were two-sided. RESULTS: The prevaccination geometric mean ELISA titer for six seropositive individuals was 202 (range, 40--640). All vaccine formulations were well tolerated, and all subjects receiving vaccine seroconverted. Serum antibody responses at 1 month after the third injection were dose dependent in recipients of vaccine without adjuvant or with MF59 but were similar at both doses when alum was the adjuvant. With the higher dose, the geometric means of serum ELISA antibody titers (95% confidence intervals) to purified VLP 1 month after the third injection were as follows: 10,240 (1499 to 69 938) without adjuvant, 10,240 (1114 to 94 145) with MF59, and 2190 (838 to 5723) with alum. Responses of subjects within each group were similar. Neutralizing and ELISA antibody titers were highly correlated (Spearman correlation =.85), confirming that ELISA titers are valid proxies for neutralizing antibodies. CONCLUSIONS: The HPV16 L1 VLP vaccine is well tolerated and is highly immunogenic even without adjuvant, with the majority of the recipients achieving serum antibody titers that were approximately 40-fold higher than what is observed in natural infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Methods for Rates and Proportions
Fleiss, J. L., Levin, B., & Paik, M. C. (2003) · Wiley Series in Probability and Statistics · doi:10.1002/0471445428 · Cited by 18,646
Practical Statistics for Medical Research.
Walter, S. D., & Altman, D. G. (1992) · Biometrics · doi:10.2307/2532320 · Cited by 11,668
Practical Statistics for Medical Research
Altman, D. G. (1990) · doi:10.1201/9780429258589 · Cited by 10,668
IARC Monographs on the Evaluation of Carcinogenic Risks to Humans
Zuckerman, A. J. (1995) · Journal of Clinical Pathology · doi:10.1136/jcp.48.7.691-a · Cited by 8,728
Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective
Bosch, F. X., Manos, M. M., Munoz, N., Sherman, M., Jansen, A. M., Peto, J., Schiffman, M. H., Moreno, V., Kurman, R., Shan, K. V., et al. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.11.796 · Cited by 3,370
Estimates of the worldwide incidence of 25 major cancers in 1990
Parkin, Pisani, P., & Ferlay, J. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990315)80:6<827::aid-ijc6>3.0.co;2-p · Cited by 2,037
Chang, M.-H., Chen, C.-J., Lai, M.-S., Hsu, H.-M., Wu, T.-C., Kong, M.-S., Liang, D.-C., Shau, W.-Y., & Chen, D.-S. (1997) · New England Journal of Medicine · doi:10.1056/nejm199706263362602 · Cited by 1,883
Estimates of the worldwide mortality from 25 cancers in 1990
Pisani, P., Parkin, D. M., Bray, F., & Ferlay, J. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990924)83:1<18::aid-ijc5>3.0.co;2-m · Cited by 1,549
Toutenburg, H. (1974) · Biometrische Zeitschrift · doi:10.1002/bimj.19740160814 · Cited by 1,538
Kirnbauer, R., Booy, F., Cheng, N., Lowy, D. R., & Schiller, J. T. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.24.12180 · Cited by 1,110
Self-citationLuckow, V. A., Lee, S. C., Barry, G. F., & Olins, P. O. (1993) · Journal of Virology · doi:10.1128/jvi.67.8.4566-4579.1993 · Cited by 912
Pisani, P., Parkin, D. M., Bray, F., & Ferlay, J. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19991210)83:6<870::aid-ijc35>3.0.co;2-9 · Cited by 860
Suzich, J. A., Ghim, S. J., Palmer-Hill, F. J., White, W. I., Tamura, J. K., Bell, J. A., Newsome, J. A., Jenson, A. B., & Schlegel, R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11553 · Cited by 668
Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles
Kirnbauer, R., Taub, J. W., Greenstone, H. L., Roden, R. B. S., Dürst, M., Gissmann, L., Lowy, D. R., & Schiller, J. T. (1993) · Journal of Virology · doi:10.1128/jvi.67.12.6929-6936.1993 · Cited by 608
Self-citationBreitburd, F., Kirnbauer, R., Hubbert, N. L., Nonnenmacher, B., Trin-Dinh-Desmarquet, C., Orth, G., Schiller, J. T., & Lowy, D. R. (1995) · Journal of Virology · doi:10.1128/jvi.69.6.3959-3963.1995 · Cited by 589
Self-citationInterim Guidelines for Management of Abnormal Cervical Cytology
Kurman, R. J. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510470070037 · Cited by 530
Rose, R. C., Bonnez, W., Reichman, R. C., & Garcea, R. L. (1993) · Journal of Virology · doi:10.1128/jvi.67.4.1936-1944.1993 · Cited by 381
Adjuvant Properties of Aluminum and Calcium Compounds
Gupta, R. K., Rost, B. E., Relyveld, E., & Siber, G. R. (1995) · Pharmaceutical Biotechnology · doi:10.1007/978-1-4615-1823-5_8 · Cited by 330
Virus-like Particles of Bovine Papillomavirus Type 4 in Prophylactic and Therapeutic Immunization
KIRNBAUER, R., CHANDRACHUD, L. M., O'NEIL, B. W., WAGNER, E. R., GRINDLAY, G. J., ARMSTRONG, A., McGARVIE, G. M., SCHILLER, J. T., LOWY, D. R., & CAMPO, M. S. (1996) · Virology · doi:10.1006/viro.1996.0220 · Cited by 313
Self-citationRoden, R. B., Greenstone, H. L., Kirnbauer, R., Booy, F. P., Jessie, J., Lowy, D. R., & Schiller, J. T. (1996) · Journal of Virology · doi:10.1128/jvi.70.9.5875-5883.1996 · Cited by 275
Self-citationChristensen, N. D., Dillner, J., Eklund, C., Carter, J. J., Wipf, G. C., Reed, C. A., Cladel, N. M., & Galloway, D. A. (1996) · Virology · doi:10.1006/viro.1996.0466 · Cited by 255
Self-citationChristensen, N. D., Reed, C. A., Cladel, N. M., Han, R., & Kreider, J. W. (1996) · Journal of Virology · doi:10.1128/jvi.70.2.960-965.1996 · Cited by 220
The influence of virus structure on antibody responses and virus serotype formation
Bachmann, M. F., & Zinkernagel, R. M. (1996) · Immunology Today · doi:10.1016/s0167-5699(96)10066-9 · Cited by 204
A Recombinant Glycoprotein Vaccine for Herpes Simplex Type 2: Safety and Efficacy
Langenberg, A. G. M., Burke, R. L., Adair, S. F., Sekulovich, R., Tigges, M., Dekker, C. L., & Corey, L. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-12-199506150-00001 · Cited by 177
Clinical Evaluation in Healthy Adults of a Hepatitis B Vaccine Made by Recombinant DNA
Scolnick, E. M. (1984) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1984.03340450028021 · Cited by 164
HPV6b virus like particles are potent immunogens without adjuvant in man
Zhang, L. (2000) · Vaccine · doi:10.1016/s0264-410x(99)00351-5 · Cited by 163
Human papillomavirus in a necessary cause of invasive cervical cancer worldwide
(1999) · Pure Amsterdam UMC · doi:10.1002/(sici)1096-9896(199909)189:1 · Cited by 140
Papillomavirus-like particles and HPV vaccine development
Schiller, J. T., & Lowy, D. R. (1996) · Seminars in Cancer Biology · doi:10.1006/scbi.1996.0046 · Cited by 119
Self-citationHeineman, T. C., Clements-Mann, M. L., Poland, G. A., Jacobson, R. M., Izu, A. E., Sakamoto, D., Eiden, J., Nest, G. A. V., & Hsu, H. H. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00088-2 · Cited by 103
Cited by
Papillomaviruses and cancer: from basic studies to clinical application
zur Hausen, H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc798 · Cited by 4,024
The causal relation between human papillomavirus and cervical cancer
Bosch, F. X., Lorincz, A., Munoz, N., Meijer, C. J. L. M., & Shah, K. V. (2002) · Journal of Clinical Pathology · doi:10.1136/jcp.55.4.244 · Cited by 3,538
Human papillomavirus and cervical cancer
Schiffman, M., Castle, P. E., Jeronimo, J., Rodriguez, A. C., & Wacholder, S. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61416-0 · Cited by 2,985
Human papillomavirus and cervical cancer
Burd, E. M. (2003) · Clinical Microbiology Reviews · doi:10.1128/cmr.16.1.1-17.2003 · Cited by 2,420
“A double-blind, randomized, placebo-controlled phase I safety and immunogenicity trial has been conducted using a subunit vaccine composed of VLP formed from the entire L1 major capsid protein of HPV-16 strain 114K (45).”
InfluentialHarper, D. M., Franco, E. L., Wheeler, C., Ferris, D. G., Jenkins, D., Schuind, A., Zahaf, T., Innis, B., Naud, P., De Carvalho, N. S., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17398-4 · Cited by 1,643
Metadata
- Authors
- Harro, C. D., Pang, Y.-Y. S., Roden, R. B. S., Hildesheim, A., Wang, Z., Reynolds, M. J., Mast, T. C., Robinson, R., Murphy, B. R., Karron, R. A., Dillner, J., Schiller, J. T., & Lowy, D. R.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-02-21
- Volume
- 93
- Issue
- 4
- Pages
- 284-292
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2154262967
- Cited by
- 607
- References
- 29
- FWCI
- 40.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.